The estimated Net Worth of Denise E Pedulla is at least $962 Tisíc dollars as of 10 November 2020. Ms. Pedulla owns over 15,000 units of Neogenomics stock worth over $962,094 and over the last 5 years she sold NEO stock worth over $0. In addition, she makes $0 as General Counsel a Corporate Secretary at Neogenomics.
Denise has made over 1 trades of the Neogenomics stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 15,000 units of NEO stock worth $117,750 on 10 November 2020.
The largest trade she's ever made was exercising 15,000 units of Neogenomics stock on 10 November 2020 worth over $117,750. On average, Denise trades about 3,000 units every 0 days since 2020. As of 10 November 2020 she still owns at least 58,988 units of Neogenomics stock.
You can see the complete history of Ms. Pedulla stock trades at the bottom of the page.
Denise E. Pedulla serves as General Counsel, Corporate Secretary of the Company. From 2011 to 2015, Ms. Pedulla served as a Principal at Berkeley Research Group in its Compliance and Regulatory Risk Management services division and was engaged in private law practice. Prior to that, from 2008 to 2011, Ms. Pedulla was the Senior Vice President and Chief Compliance Officer at Orthofix International NV, a global orthopedic medical device company. From 2000 to 2008, Ms. Pedulla, a health care lawyer, was engaged in private law practice and provided legal counsel to hospitals, clinical laboratories, durable medical equipment suppliers and other health care providers in the areas of fraud and abuse, coverage, billing and reimbursement, regulatory compliance, corporate governance, contracting, and government affairs. From 1996 to 2000, Ms. Pedulla was employed at Fresenius Medical Care North America in positions of increasing responsibility, including Associate General Counsel and Vice President of Compliance, Regulatory and Government Affairs for the company’s clinical laboratory division. Ms. Pedulla received a B.S. in Nursing and Psychology from Boston College, a J.D. from Suffolk Law School, and an M.P.H. in Health Policy and Management from Harvard University. She also holds a Certification in Health Care Compliance (CHC) from the Health Care Compliance Association. Ms. Pedulla is a licensed attorney in Massachusetts and Florida and is a member of the Association of Corporate Council, the American Health Lawyers Association and the Health Law Sections of the American, Florida, and Massachusetts Bar Associations.
Denise Pedulla is 60, she's been the General Counsel a Corporate Secretary of Neogenomics since 2019. There are 6 older and 19 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Denise's mailing address filed with the SEC is C/O CONFORMIS INC, 600 TECHNOLOGY PARK DRIVE, BILLERICA, MA, 01821.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van a Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: